medvisМедицинская визуализацияMedical Visualization1607-07632408-9516RDS-Media Ltd.10.24835/1607-0763-2019-4-114-130medvis-844Research ArticleНОВЫЕ ТЕХНОЛОГИИ ЛУЧЕВЫХ ИССЛЕДОВАНИЙNEW TECHNOLOGIES IN RADIOLOGYБиохимические основы визуализации при позитронной эмиссионной томографии в онкологии. Часть 1Biochemical basics of imaging in positron emission tomography in oncology. Part 1ЛеонтьевА. В.LeontyevA. V.

канд. мед. наук, заведующий отделением радионуклидной диагностики

125284, Москва, 2-й Боткинский проезд, д. 3

Тел.: +7-495-945-87-18

Cand. of Sci. (Med.), Head of Nuclear Medicine Department

3, 2 nd Botkinsky pr., Moscow, 125284

Phone: +7-495-945-87-18

aleksleont@yandex.ruhttps://orcid.org/0000-0001-8378-4338РубцоваН. А.RubtsovaN. A.

доктор мед. наук, руководитель отдела лучевой диагностики

Dr. of Sci. (Med.), Head of Radiology Department

rna17@yandex.ruhttps://orcid.org/0000-0002-8905-4202ХалимонА. И.KhalimonA. I.

врач-рентгенолог отделения КТ и МРТ

radiologist of CT and MRI Department

markyhaws@gmail.comhttps://orcid.org/0000-0002-4864-0643ХамадееваГ. Ф.KhamadeevaG. F.

Resident of Nuclear Medicine Department

g.hamadeeva@yandex.ruhttps://orcid.org/0000-0002-3508-1782КулиевМ. Т.KulievM. T.

клинический ординатор кафедры онкологии, радиотерапии и пластической хирургии лечебного факультета ФГАОУ ВО Первый МГМУ имени И.М. Сеченова (Сеченовский Университет) на базе отделения радионуклидной диагностики

Resident of Oncology, Radiotherapy and Plastic Surgery Department of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) based at the Nuclear Medicine Department

kul502@yandex.ruhttps://orcid.org/0000-0002-1280-620XПыловаИ. В.PylovaI. V.

канд. мед. наук, врач-радиолог отделения радионуклидной диагностики

Cand. of Sci. (Med.), nuclear medicine physician of Nuclear Medicine Department

irinapylova@mail.ruhttps://orcid.org/0000-0002-7835-4939ЛазутинаТ. Н.LazutinaT. N.

канд. мед. наук, врач-радиолог отделения радионуклидной диагностики

Cand. of Sci. (Med.), nuclear medicine physician of Nuclear Medicine Department

t.n.lazutina@yandex.ruhttps://orcid.org/0000-0002-0792-6012КостинА. А.KostinA. A.

доктор мед. наук, профессор, первый заместитель генерального директора

Dr. of Sci. (Med.), Professor, First Deputy of General director

andocrey@mail.ruhttps://orcid.org/0000-0001-8784-8415КапринА. Д.KaprinA. D.

академик РАН, доктор мед. наук, профессор, главный уролог РАН, заслуженный врач РФ, генеральный директор

Full Member of the Russian Academy of Sciences, Dr. of Sci. (Med.), Professor, Honored Doctor of the Russian Federation; Chief urologist of the Russian Academy of Sciences, General Director

kaprin@mail.ruМНИОИ имени П.А. Герцена – филиал ФГБУ “Национальный медицинский исследовательский центр радиологии” Минздрава РоссииРоссияP.A. Herzen Moscow Research Oncology Institute – branch of “National Medical Research Center of Radiology” of the Ministry of Healthcare of RussiaRussian Federation20192512201904114130Copyright © Леонтьев А.В., Рубцова Н.А., Халимон А.И., Хамадеева Г.Ф., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Костин А.А., Каприн А.Д., 20192019Леонтьев А.В., Рубцова Н.А., Халимон А.И., Хамадеева Г.Ф., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Костин А.А., Каприн А.Д.Leontyev A.V., Rubtsova N.A., Khalimon A.I., Khamadeeva G.F., Kuliev M.T., Pylova I.V., Lazutina T.N., Kostin A.A., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medvis.rdsmedia.ru/jour/article/view/844

Настоящая статья содержит обзор основных литературных данных, посвященных биохимическим основам клинического применения позитронной эмиссионной томографии - одной из наиболее перспективных технологий лучевой визуализации в онкологии. В первой части рассмотрены особенности биокинетики метаболических радиофармацевтических препаратов, таких как 18F-фтордезоксиглюкоза, радиомеченые маркеры липидного обмена 11С- и 18F-холин, 11C-ацетат, а также аналоги аминокислот 18F-дигидроксифенилаланин, 11C метионин, 18F-фторэтилтирозин, 11C-триптофан, 18F-флуцикловин. Кратко представлены результаты исследований, посвященных оценке эффективности, основные показания к применению, а также перспективные научные разработки в данной отрасли.

This article provides a literature overview of biochemical basics and the clinical application of positron emission tomography, one of the most promising technologies of nuclear imaging in oncology. In the first part we discuss the biokinetics of metabolic radiopharmaceuticals, such as 18F-fluorodeoxyglucose, radiolabeled markers of lipid metabolism 11C- and 18F-choline, 11C-acetate, as well as amino acids analogues – 18F-dihydroxyphenylalanine, 11C-methionine, 18F-fluoroe thyltyrosine, 11C-tryptophan, 18F-flucyclovine. This article includes results of scientific researches, that studied radiopharmaceuticals’ effectiveness in oncological practice. The main indications for use, as well as promising scientific developments in this industry are presented.

ПЭТ/КТРФПФДГхолинацетатДОФАтриптофанФЭТфлуцикловинPET/CTradiopharmaceuticalsmetabolic processesaminoacid analoguesfluordeoxyglucosecholineacetatefluciclovineDOPAtryptophanfluorethyltyrosinethymidineReferencesPhelps M.E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 2000; 41 (4): 661–681.Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 2000; 41 (4): 661–681.Anand S.S., Singh H., Dash A.K. Clinical Applications of PET and PET-CT. Med. J. Armed. Forces India. 2009; 65 (4): 353–358.Anand S.S., Singh H., Dash A.K. Clinical Applications of PET and PET-CT. Med. J. Armed. Forces India. 2009; 65 (4): 353–358.Wadsaka W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur. J. Radiology. 2010; 73 (3): 461–469. https://doi.org/10.1016/j.ejrad.2009.12.022Wadsaka W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur. J. Radiology. 2010; 73 (3): 461–469. https://doi.org/10.1016/j.ejrad.2009.12.022Fanti S., Farsad M., Mansi L. PET-CT Beyond FDG. A Quick Guide to Image Interpretation. Berlin; Heidelberg: Springer-Verlag, 2010.Fanti S., Farsad M., Mansi L. PET-CT Beyond FDG. A Quick Guide to Image Interpretation. Berlin; Heidelberg: Springer-Verlag, 2010.Ido T., Wan C.N., Casella V., Fowler J.S., Wolf A.P., Reivich M., Kuhl D.E. Labeled 2-deoxy-d-glucose analogs – F-18- labeled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-dmannose and C-14- 2-deoxy-2-fluoro-d-glucose. J. Label Compd. Radiopharm. 1978; 14 (2): 175–183. https://doi.org/10.1002/jlcr.2580140204Ido T., Wan C.N., Casella V., Fowler J.S., Wolf A.P., Reivich M., Kuhl D.E. Labeled 2-deoxy-d-glucose analogs – F-18- labeled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-dmannose and C-14- 2-deoxy-2-fluoro-d-glucose. J. Label Compd. Radiopharm. 1978; 14 (2): 175–183. https://doi.org/10.1002/jlcr.2580140204Gallagher B.M., Ansari A., Atkins H., Casella V., Christman D.R., Fowler J.S., Ido T., MacGregor R.R., Som P., Wan C.N., Wolf A.P., Kuhl D.E., Reivich M. F-18-Gallagher B.M., Ansari A., Atkins H., Casella V., Christman D.R., Fowler J.S., Ido T., MacGregor R.R., Som P., Wan C.N., Wolf A.P., Kuhl D.E., Reivich M. F-18-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucosemetabolism invivo – tissue distribution and imaging studies in animals. J. Nucl. Med. 1977; 18 (10): 990–996.labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucosemetabolism invivo – tissue distribution and imaging studies in animals. J. Nucl. Med. 1977; 18 (10): 990–996.Boellaard R., Delgado-Bolton R., Oyen W.J.G., Giammarile F., Tatsch K., Eschner W. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42: 328–354. https://doi.org/10.1007/s00259-014-2961-xBoellaard R., Delgado-Bolton R., Oyen W.J.G., Giammarile F., Tatsch K., Eschner W. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42: 328–354. https://doi.org/10.1007/s00259-014-2961-xКуликов В.А., Беляева Л.Е. О биоэнергетике опухолевой клетки. Вестник ВГМУ. 2015; 14 (6): 5–14.Kulikov V.A., Belyaeva L.E. On bioenergetics of a tumoral cell. Vestnik VGMU. 2015; 14 (6): 5–14. (In Russian)Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66 (18): 8927–8930. https://doi.org/10.1158/0008-5472.CAN-06-1501Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66 (18): 8927–8930. https://doi.org/10.1158/0008-5472.CAN-06-1501Mueckler M. Facilitative glucose transporters. Eur. J. Biochem. 1994; 219 (3): 713–725.Mueckler M. Facilitative glucose transporters. Eur. J. Biochem. 1994; 219 (3): 713–725.Zhu A., Lee D., Shim H. Metabolic PET Imaging in Cancer Detection and Therapy Response. Semin. Oncol . 2011; 38 (1): 55–69. https://doi.org/10.1053/j.seminoncol.2010.11.012Zhu A., Lee D., Shim H. Metabolic PET Imaging in Cancer Detection and Therapy Response. Semin. Oncol . 2011; 38 (1): 55–69. https://doi.org/10.1053/j.seminoncol.2010.11.012Larson S.M. 18F-FDG Imaging: Molecular or Functional? J. Nucl. Med. 2006; 47: 31N–32N.Larson S.M. 18F-FDG Imaging: Molecular or Functional? J. Nucl. Med. 2006; 47: 31N–32N.Jensen M.M., Kjaer A. Monitoring of anti-cancer treatment with 18F-FDG and 18F-FLT PET: a comprehensive review of pre-clinical studies. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (5): 431–456.Jensen M.M., Kjaer A. Monitoring of anti-cancer treatment with 18F-FDG and 18F-FLT PET: a comprehensive review of pre-clinical studies. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (5): 431–456.Mochizuki T., Tsukamoto E., KugeY., Kanegae K., Zhao S., Hikosaka K., Hosokawa M., Kohanawa M., Tamaki N. FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models. J. Nucl. Med. 2001; 42 (10): 1551–1555.Mochizuki T., Tsukamoto E., KugeY., Kanegae K., Zhao S., Hikosaka K., Hosokawa M., Kohanawa M., Tamaki N. FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models. J. Nucl. Med. 2001; 42 (10): 1551–1555.Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut 1 and Glut 3 in stage I non-small cell lung carcinoma is associated with poor survival. Cancer. 1997; 80: 1046–1051.Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut 1 and Glut 3 in stage I non-small cell lung carcinoma is associated with poor survival. Cancer. 1997; 80: 1046–1051.Kwee S.A., Hernandez B., Chan O., Wong L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One. 2012; 7: 46–59. https://doi.org/10.1371/journal.pone.0046591Kwee S.A., Hernandez B., Chan O., Wong L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One. 2012; 7: 46–59. https://doi.org/10.1371/journal.pone.0046591Palmieri D., Fitzgerald D., Shreeve S.M., Hua E., Bronder J.L., Weil R.J., Davis S., Stark A.M., Merino M.J., Kurek R., Mehdorn H.M., Davis G., Steinberg S.M., Meltzer P.S., Aldape K., Steeg P.S. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol. Cancer Res. 2009; 7: 1438–1445. https://doi.org/10.1158/1541-7786.MCR-09-0234Palmieri D., Fitzgerald D., Shreeve S.M., Hua E., Bronder J.L., Weil R.J., Davis S., Stark A.M., Merino M.J., Kurek R., Mehdorn H.M., Davis G., Steinberg S.M., Meltzer P.S., Aldape K., Steeg P.S. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol. Cancer Res. 2009; 7: 1438–1445. https://doi.org/10.1158/1541-7786.MCR-09-0234Park S., Lee E., Rhee S., Cho J., Choi S., Lee S., Eo J.S., Pahk K., Choe J.G., Kim S. Correlation between Semi- Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer. Nucl. Med. Mol. Imaging. 2016; 50 (1): 24–30. https://doi.org/10.1007/s13139-015-0363-zPark S., Lee E., Rhee S., Cho J., Choi S., Lee S., Eo J.S., Pahk K., Choe J.G., Kim S. Correlation between Semi- Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer. Nucl. Med. Mol. Imaging. 2016; 50 (1): 24–30. https://doi.org/10.1007/s13139-015-0363-zHan B., Lin S., Yu L.J., Wang R.Z., Wang Y.Y. Correlation of 18F-FDG PET activity with expressions of survivin, Ki-67, and CD34 in non-small-cell lung cancer. Nucl. Med. Commun. 2009; 30: 831–837. https://doi.org/10.1097/MNM.0b013e32832dcfc4Han B., Lin S., Yu L.J., Wang R.Z., Wang Y.Y. Correlation of 18F-FDG PET activity with expressions of survivin, Ki-67, and CD34 in non-small-cell lung cancer. Nucl. Med. Commun. 2009; 30: 831–837. https://doi.org/10.1097/MNM.0b013e32832dcfc4Koo H.R., Park J.S., Kang K.W., Han W., Park I.A., Moon W.K. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur. Radiol. 2015; 25 (11): 3314–3321. https://doi.org/10.1007/s00330-015-3734-zKoo H.R., Park J.S., Kang K.W., Han W., Park I.A., Moon W.K. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur. Radiol. 2015; 25 (11): 3314–3321. https://doi.org/10.1007/s00330-015-3734-zLiang Y., Wu N., Fang Y., Huang W.T., Zhang H., Zheng R., Zhang W.J., Liu Y., Li X.M. Correlation of 18F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma. Zhonghua Zhong Liu Za Zhi. 2013; 35 (5): 356–360. https://doi.org/10.3760/cma.j.issn.0253-3766.2013.05.008Liang Y., Wu N., Fang Y., Huang W.T., Zhang H., Zheng R., Zhang W.J., Liu Y., Li X.M. Correlation of 18F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma. Zhonghua Zhong Liu Za Zhi. 2013; 35 (5): 356–360. https://doi.org/10.3760/cma.j.issn.0253-3766.2013.05.008Deng S.M., Zhang W., Zhang B., Chen Y.Y., Li J.H., Wu Y.W. Correlation between the uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the expression of proliferation- associated antigen Ki-67 in cancer patients: a metaanalysis. PLoS One. 2015; 10 (6). https://doi.org/10.1371/journal.pone.0129028Deng S.M., Zhang W., Zhang B., Chen Y.Y., Li J.H., Wu Y.W. Correlation between the uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the expression of proliferation- associated antigen Ki-67 in cancer patients: a metaanalysis. PLoS One. 2015; 10 (6). https://doi.org/10.1371/journal.pone.0129028Березов Т.Т., Коровкин Б.Ф. Биологическая химия: Учебник. 3-е изд., перераб. и доп. Учеб. лит. для студентов мед. вузов. М.: Медицина, 1998.Berezov T.T., Korovkin B.F. Biological chemistry: Textbook. 3rd ed., revised. and add. Textbook. lit. Forstudents, honey. universities. M.: Medicine, 1998. (In Russian)Müller S.A., Holzapfel K., Seidl C., Treiber U., Krause B.J., Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur. J. Nucl. Med. Mol. Imaging. 2009; 36: 1434–1442. https://doi.org/10.1007/s00259-009-1117-xMüller S.A., Holzapfel K., Seidl C., Treiber U., Krause B.J., Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur. J. Nucl. Med. Mol. Imaging. 2009; 36: 1434–1442. https://doi.org/10.1007/s00259-009-1117-xKennedy E.P., Weiss S.B. The function of cytidine coenzymes in the biosynthesis of phospholipides. J. Biol. Chem. 1956; 222: 193–214.Kennedy E.P., Weiss S.B. The function of cytidine coenzymes in the biosynthesis of phospholipides. J. Biol. Chem. 1956; 222: 193–214.Nanni C., Zamagni E., Cavo M., Rubello D., Tacchetti P., Pettinato C., Farsad M., Castellucci P., Ambrosini V., Montini G.C., Al-Nahhas A., Franchi R., Fanti S. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. Wld J. Surg. Oncol. 2007; 5: 68. https://doi.org/10.1186/1477-7819-5-68.Nanni C., Zamagni E., Cavo M., Rubello D., Tacchetti P., Pettinato C., Farsad M., Castellucci P., Ambrosini V., Montini G.C., Al-Nahhas A., Franchi R., Fanti S. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. Wld J. Surg. Oncol. 2007; 5: 68. https://doi.org/10.1186/1477-7819-5-68.Kato T., Shinoda J., Nakayama N., Miwa K., Okumura A., Yano H., Yoshimura S., Maruyama T., Muragaki Y., Iwama T. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positronemission tomography. Am. J. Neuroradiol. 2008; 29: 1176–1182. https://doi.org/10.3174/ajnr.A1008Kato T., Shinoda J., Nakayama N., Miwa K., Okumura A., Yano H., Yoshimura S., Maruyama T., Muragaki Y., Iwama T. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positronemission tomography. Am. J. Neuroradiol. 2008; 29: 1176–1182. https://doi.org/10.3174/ajnr.A1008Yano H., Shinoda J., Iwama T. Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma. Neurol. Med. Chir. 2017; 57 (7): 312–320. https://doi.org/10.2176/nmc.ra.2016-0312Yano H., Shinoda J., Iwama T. Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma. Neurol. Med. Chir. 2017; 57 (7): 312–320. https://doi.org/10.2176/nmc.ra.2016-0312Kim S.J., Koo P.J., Pak K., Kim I.J., Kim K. Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis. Wld J. Urol. 2018; 36 (3): 331–340. https://doi.org/10.1007/s00345-017-2168-4Kim S.J., Koo P.J., Pak K., Kim I.J., Kim K. Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis. Wld J. Urol. 2018; 36 (3): 331–340. https://doi.org/10.1007/s00345-017-2168-4Тулин П.Е., Долгушин М.Б., Оджарова А.А., Михайлов А.И., Невзоров Д.И., Медведева Б.М. ПЭТ/ КТ с 18F-ФДГ и 18F-холином в комплексной диагностике диссеминированного гепатоцеллюлярного рака у пациента семи лет (клиническое наблюдение). Медицинская визуализация. 2016; (5): 67–73. https://doi.org/10.21294/1814-4861-2018-17-5-111-118.Tulin P.E., Dolgushin M.B., Odzharova A.A., Mikhailov A.I., Nevzorov D.I., Medvedeva B.M. PET/CT witH 18F-FDG and 18F-Choline in the Complex Diagnostics of Disseminated Hepatocellular Cancer in the Patient Seven Years Old (Clinical Case). Medical Visualization. 2016; 5: 67–73. https://doi.org/10.21294/1814-4861-2018-17-5-111-118 (In Russian)Vali R., Loidl W., Pirich C., Langesteger W., Beheshti M. Imaging of prostate cancer with PET/CT using 18F-Fluorocholine. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (2): 96–108.Vali R., Loidl W., Pirich C., Langesteger W., Beheshti M. Imaging of prostate cancer with PET/CT using 18F-Fluorocholine. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (2): 96–108.Асланиди И.П., Пурсанова Д.М., Мухортова О.В., Сильченков А.В., Рощин Д.А., Корякин А.В., Иванов С.А., Широкорад В.И. ПЭТ/КТ с 11С-холином в диагностике рецидива рака предстательной железы у пациентов с биохимическим прогрессированием. Онкоурология. 2015; 11 (3): 79–86. https://doi.org/ 10.17650/1726-9776-2015-11-3-79-86Aslanidis I.P., Pursanova D.M., Mukhortova O.V., Silchenkov A.V., Roshin D.A., Koryakin A.V., Ivanov S.A., Shirokorad V.I. 11C-Choline PET / CT in the detection of prostate cancer relapse in patients with rising PSA. Cancer Urology. 2015; 11 (3): 79–86. https://doi.org/10.17650/1726-9776-2015-11-3-79-86 (In Russian).Von Eyben F.E., Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nuclear Med. Communications. 2014; 35 (3): 221–230. https://doi.org/10.1097/mnm.0000000000000040Von Eyben F.E., Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nuclear Med. Communications. 2014; 35 (3): 221–230. https://doi.org/10.1097/mnm.0000000000000040Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010; C-254 (N 3): 925–933.Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010; C-254 (N 3): 925–933.DeGrado T.R., Baldwin S.W., Wang S., Orr M.D., Liao R.P., Friedman H.S., Reiman R., Price D.T., Coleman R.E. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J. Nucl. Med. 2001; 42 (12): 1805–1814.DeGrado T.R., Baldwin S.W., Wang S., Orr M.D., Liao R.P., Friedman H.S., Reiman R., Price D.T., Coleman R.E. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J. Nucl. Med. 2001; 42 (12): 1805–1814.Waniewski R.A., Martin D.L. Preferential utilization of acetate by astrocytes is attributable to transport. J. Neuroscience. 1998; 18 (14): 5225–5233.Waniewski R.A., Martin D.L. Preferential utilization of acetate by astrocytes is attributable to transport. J. Neuroscience. 1998; 18 (14): 5225–5233.Swinnen J.V., Van Veldhoven P.P., Timmermans L., De Schrijver E., Brusselmans K., Vanderhoydonc F., Van de Sande T., Heemers H., Heyns W., Verhoeven G. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun. 2003; 302: 898–903.Swinnen J.V., Van Veldhoven P.P., Timmermans L., De Schrijver E., Brusselmans K., Vanderhoydonc F., Van de Sande T., Heemers H., Heyns W., Verhoeven G. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun. 2003; 302: 898–903.Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., Takahashi N., Welch M.J., Fujibayashi Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol. 2001; 28: 117–122.Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., Takahashi N., Welch M.J., Fujibayashi Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol. 2001; 28: 117–122.Karanikas G., Beheshti M. 11C-Acetate PET/CT Imaging Physiologic Uptake, Variants, and Pitfalls. PET clinics. 2014; 9 (3): 339–344. https://doi.org/10.1016/j.cpet.2014.03.006Karanikas G., Beheshti M. 11C-Acetate PET/CT Imaging Physiologic Uptake, Variants, and Pitfalls. PET clinics. 2014; 9 (3): 339–344. https://doi.org/10.1016/j.cpet.2014.03.006Masanao N., Tamaki N. Imaging of Myocardial Oxidative Metabolism in Heart Failure. Current Cardiovasc. Imaging Rep. 2014; 7 (1): 9244. https://doi.org/10.1007/s12410-013-9244-yMasanao N., Tamaki N. Imaging of Myocardial Oxidative Metabolism in Heart Failure. Current Cardiovasc. Imaging Rep. 2014; 7 (1): 9244. https://doi.org/10.1007/s12410-013-9244-ySoloviev D., Fini A., Chierichetti F., Al-Nahhas A., Rubello D. PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (5): 942–949. https://doi.org/10.1007/s00259-007-0662-4Soloviev D., Fini A., Chierichetti F., Al-Nahhas A., Rubello D. PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (5): 942–949. https://doi.org/10.1007/s00259-007-0662-4Huo L., Dang Y., Lv J., Xing H., Li F. Application of Dual Phase Imaging of 11C-Acetate Positron Emission Tomography on Differential Diagnosis of Small Hepatic Lesions. PLoS One. 2014; 9 (5). https://doi.org/10.1371/journal.pone.0096517Huo L., Dang Y., Lv J., Xing H., Li F. Application of Dual Phase Imaging of 11C-Acetate Positron Emission Tomography on Differential Diagnosis of Small Hepatic Lesions. PLoS One. 2014; 9 (5). https://doi.org/10.1371/journal.pone.0096517Huo L., Wu Z., Zhuang H., Fu Z., Dang Y. Dual time point 11C-acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin. Nucl. Med. 2009; 34: 874–877. https://doi.org/10.1371/journal.pone.0096517Huo L., Wu Z., Zhuang H., Fu Z., Dang Y. Dual time point 11C-acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin. Nucl. Med. 2009; 34: 874–877. https://doi.org/10.1371/journal.pone.0096517Schöder H., Ong S.C., Reuter V.E., Cai S., Burnazi E., Dalbagni G., Larson S.M., Bochner B.H. Initial results with 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol. Imaging Biol. 2012; 14: 245–251. https://doi.org/10.1007/s11307-011-0488-0Schöder H., Ong S.C., Reuter V.E., Cai S., Burnazi E., Dalbagni G., Larson S.M., Bochner B.H. Initial results with 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol. Imaging Biol. 2012; 14: 245–251. https://doi.org/10.1007/s11307-011-0488-0Liu R.S., Chang C.P., Guo W.Y., Pan D.H., Ho D.M., Chang C.W., Yang B.H., Wu L.C., Yeh S.H. 11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J. Nucl. Med. 2010; 51: 883–891. https://doi.org/10.2967/jnumed.109.070565Liu R.S., Chang C.P., Guo W.Y., Pan D.H., Ho D.M., Chang C.W., Yang B.H., Wu L.C., Yeh S.H. 11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J. Nucl. Med. 2010; 51: 883–891. https://doi.org/10.2967/jnumed.109.070565Mena E., Turkbey B., Mani H., Adler S., Valera V.A., Bernardo M., Shah V., Pohida T., McKinney Y., Kwarteng G., Daar D., Lindenberg M.L., Eclarinal P., Wade R., Linehan W.M., Merino M.J., Pinto P.A., Choyke P.L., Kurdziel K.A. 11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation. J. Nucl. Med. 2012; 53 (4): 538–545. https://doi.org/10.2967/jnumed.111.096032Mena E., Turkbey B., Mani H., Adler S., Valera V.A., Bernardo M., Shah V., Pohida T., McKinney Y., Kwarteng G., Daar D., Lindenberg M.L., Eclarinal P., Wade R., Linehan W.M., Merino M.J., Pinto P.A., Choyke P.L., Kurdziel K.A. 11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation. J. Nucl. Med. 2012; 53 (4): 538–545. https://doi.org/10.2967/jnumed.111.096032Langen K.J., Hamacher K., Weckesser M., Floeth F., Stoffels G., Bauer D., Coenen H.H., Pauleit D. O-(2-[18F]. fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 2006; 33: 287–294. https://doi.org/10.1016/j.nucmedbio.2006.01.002Langen K.J., Hamacher K., Weckesser M., Floeth F., Stoffels G., Bauer D., Coenen H.H., Pauleit D. O-(2-[18F]. fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 2006; 33: 287–294. https://doi.org/10.1016/j.nucmedbio.2006.01.002Heiss P., Mayer S., Herz M., Wester H.J., Schwaiger M., Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)- l-tyrosine in vitro and in vivo. J. Nucl. Med. 1999; 40: 1367–1373. https://doi.org/10.1515/raon-2016-0022Heiss P., Mayer S., Herz M., Wester H.J., Schwaiger M., Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)- l-tyrosine in vitro and in vivo. J. Nucl. Med. 1999; 40: 1367–1373. https://doi.org/10.1515/raon-2016-0022Haase C., Bergmann R., Fuechtner F., Hoepping A., Pietzsch J. L-type amino acid transporters LAT1 and LAT4 in cancer: Uptake of 3-O-Methyl-6-18F-Fluoro-L-Dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J. Nucl. Med. 2007; 48 (12): 2063–2071. https://doi.org/10.2967/jnumed.107.043620Haase C., Bergmann R., Fuechtner F., Hoepping A., Pietzsch J. L-type amino acid transporters LAT1 and LAT4 in cancer: Uptake of 3-O-Methyl-6-18F-Fluoro-L-Dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J. Nucl. Med. 2007; 48 (12): 2063–2071. https://doi.org/10.2967/jnumed.107.043620Umeki N., Fukasawa Y., Ohtsuki S., Hori S., Watanabe Y., Kohno Y., Terasaki T. mRNA expression and amino acid transport characteristics of cultured human brain microvascular endothelial cells (hBME). Drug Metab. Pharmacokinet. 2002; 17: 367–373.Umeki N., Fukasawa Y., Ohtsuki S., Hori S., Watanabe Y., Kohno Y., Terasaki T. mRNA expression and amino acid transport characteristics of cultured human brain microvascular endothelial cells (hBME). Drug Metab. Pharmacokinet. 2002; 17: 367–373.Uchino H., Kanai Y., Kim D.K., Wempe M.F., Chairoungdua A., Morimoto E., Anders M.W., Endou H. Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. Molecular Pharmacology. 2002; 61 (4): 729–737.Uchino H., Kanai Y., Kim D.K., Wempe M.F., Chairoungdua A., Morimoto E., Anders M.W., Endou H. Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. Molecular Pharmacology. 2002; 61 (4): 729–737.Рыжкова Д.В., Тихонова Д.Н., Гринева Е.Н. Методы ядерной медицины в диагностике нейроэндокринных опухолей. Сибирский онкологический журнал. 2013; 6 (60): 56–63.Ryzhkova D.V., Тikhonova D.N., Grineva E.N. Nuclear medicine technology for diagnosisof neuroendocrine tumors. Siberian journal of oncology. 2013; 1 (6): 56–63. (In Russian)Pretze M., Wängler C., Wängler B. 6-[18F]Fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. BioMed. Res. Int. Доступно по: www.hindawi.com/journals/bmri/2014/674063/ Ссылка активна на 14.05.2019.Pretze M., Wängler C., Wängler B. 6-[18F]Fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. BioMed. Res. Int. Доступно по: www.hindawi.com/journals/bmri/2014/674063/ Ссылка активна на 14.05.2019.Stoessl A.J. Developments in neuroimaging: positron emission tomography. Parkinsonism Relat. Disord. 2014; 20: 180–183. https://doi.org/10.1016/j.neubiorev.2015.09.007Stoessl A.J. Developments in neuroimaging: positron emission tomography. Parkinsonism Relat. Disord. 2014; 20: 180–183. https://doi.org/10.1016/j.neubiorev.2015.09.007Губаева Д.Н., Меликян М.А., Рыжкова Д.В., Ники- тина И.Л. ПЭТ/КТ с 18F-ДОФА при врожденном гиперинсулинизме. REJR. 2017; 7 (3): 144–152. https://doi. org/10.21569/2222-7415-2017-7-3-144-152 Gubaeva D.N., Melikyan M.A., Ryzhkova D.V., Nikitina I.L. The use of 18FDOPA PET/CT imaging in congenital hyperinsulinism. REJR. 2017; 7 (3): 144–152. https://doi.org/10.21569/2222-7415-2017-7-3-144-152 (In Russian)Губаева Д.Н., Меликян М.А., Рыжкова Д.В., Никитина И.Л. ПЭТ/КТ с 18F-ДОФА при врожденном гиперинсулинизме. REJR. 2017; 7 (3): 144–152. https://doi. org/10.21569/2222-7415-2017-7-3-144-152 Gubaeva D.N., Melikyan M.A., Ryzhkova D.V., Nikitina I.L. The use of 18FDOPA PET/CT imaging in congenital hyperinsulinism. REJR. 2017; 7 (3): 144–152. https://doi.org/10.21569/2222-7415-2017-7-3-144-152 (In Russian)Bozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-yBozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-yBozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Sundin A., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTAconjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-yBozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Sundin A., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTAconjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-yRufini V., Treglia G., Montravers F., Giordano A. Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin. Translat. Imaging. 2013; 1 (2): 111–122. https://doi.org/10.1007/s40336-013-0005-3Rufini V., Treglia G., Montravers F., Giordano A. Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin. Translat. Imaging. 2013; 1 (2): 111–122. https://doi.org/10.1007/s40336-013-0005-3Juhász C., Dwivedi S., Kamson D.O., Michelhaugh S.K., Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol. Imaging. 2014; 13. https://doi.org/10.2310/7290.2014.00015Juhász C., Dwivedi S., Kamson D.O., Michelhaugh S.K., Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol. Imaging. 2014; 13. https://doi.org/10.2310/7290.2014.00015Ribeiro M.J., De Lonlay P., Delzescaux T., Boddaert N., Jaubert F., Bourgeois S., Dollé F., Nihoul-Fékété C., Syrota A., Brunelle F. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. J. Nucl. Med. 2005; 46: 560–566.Ribeiro M.J., De Lonlay P., Delzescaux T., Boddaert N., Jaubert F., Bourgeois S., Dollé F., Nihoul-Fékété C., Syrota A., Brunelle F. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. J. Nucl. Med. 2005; 46: 560–566.Timmers H.J., Hadi M., Carrasquillo J.A., Chen C.C., Martiniova L., Whatley M., A. Ling, Eisenhofer G., Adams K.T., Pacak K. The effects of carbidopa on uptake of 6-18-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J. Nucl. Med. 2007; 48: 1599–1606. https://doi.org/10.2967/jnumed.107.042721Timmers H.J., Hadi M., Carrasquillo J.A., Chen C.C., Martiniova L., Whatley M., A. Ling, Eisenhofer G., Adams K.T., Pacak K. The effects of carbidopa on uptake of 6-18-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J. Nucl. Med. 2007; 48: 1599–1606. https://doi.org/10.2967/jnumed.107.042721Calabria F.F., Chiaravalloti A., Jaffrain-Rea M.L., Zinzi M., Sannino P., Minniti G., Rubello D., Schillaci O. 18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients. Clin. Nucear. Med. 2016; 41 (10): 753–760. https://doi.org/10.1097/RLU.0000000000001318Calabria F.F., Chiaravalloti A., Jaffrain-Rea M.L., Zinzi M., Sannino P., Minniti G., Rubello D., Schillaci O. 18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients. Clin. Nucear. Med. 2016; 41 (10): 753–760. https://doi.org/10.1097/RLU.0000000000001318Ito K., Matsuda H., Kubota K. Imaging spectrum and pitfalls of 11C-Methionine positron emission tomography in a series of patients with intracranial lesions. Korean J. Radiol. 2016; 17 (3): 424–434. https://doi.org/10.3348/kjr.2016.17.3.424Ito K., Matsuda H., Kubota K. Imaging spectrum and pitfalls of 11C-Methionine positron emission tomography in a series of patients with intracranial lesions. Korean J. Radiol. 2016; 17 (3): 424–434. https://doi.org/10.3348/kjr.2016.17.3.424Nakajima R., Koichiro K.K., Sakai A.S. 11C-methionine PET/CT findings in benign brain disease. Japanese J. Radiol. 2017; 35 (6): 279–288. https://doi.org/10.1007/s11604-017-0638-7Nakajima R., Koichiro K.K., Sakai A.S. 11C-methionine PET/CT findings in benign brain disease. Japanese J. Radiol. 2017; 35 (6): 279–288. https://doi.org/10.1007/s11604-017-0638-7Palanichamy K., Chakravarti A. Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas. Frontiers in Oncol. 2017; 7: 257. https://doi.org/10.3389/fonc.2017.00257Palanichamy K., Chakravarti A. Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas. Frontiers in Oncol. 2017; 7: 257. https://doi.org/10.3389/fonc.2017.00257Xu W., Gao L., Shao A., Zheng J., Zhang J. The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. Oncotarget. 2017; 8 (53), 91030–91039. https://doi.org/10.18632/oncotarget.19024Xu W., Gao L., Shao A., Zheng J., Zhang J. The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. Oncotarget. 2017; 8 (53), 91030–91039. https://doi.org/10.18632/oncotarget.19024Heiss P., Mayer S., Herz M., Wester H.J., Schwaiger M., Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)- l-tyrosine in vitro and in vivo. J. Nucl. Med. 1999; 40: 1367–1373. https://doi.org/10.1515/raon-2016-0022Heiss P., Mayer S., Herz M., Wester H.J., Schwaiger M., Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)- l-tyrosine in vitro and in vivo. J. Nucl. Med. 1999; 40: 1367–1373. https://doi.org/10.1515/raon-2016-0022Abdelwahab M.A., Omar W. F18-FET PET/CT in brain tumors. Egyptian J. Nucl. Med. 2016; 13 (13): 1–6. https://doi.org/10.21608/EGYJNM.2016.3308Abdelwahab M.A., Omar W. F18-FET PET/CT in brain tumors. Egyptian J. Nucl. Med. 2016; 13 (13): 1–6. https://doi.org/10.21608/EGYJNM.2016.3308Pauleit D., Floeth F., Herzog H., Hamacher K., Tellmann L., Müller H.W., Coenen H.H., Langen K.J. Whole-body distribution and dosimetry of O-(2-[18F] fluoroethyl)-ltyrosine. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 519–524. https://doi.org/10.1007/s00259-003-1118-0Pauleit D., Floeth F., Herzog H., Hamacher K., Tellmann L., Müller H.W., Coenen H.H., Langen K.J. Whole-body distribution and dosimetry of O-(2-[18F] fluoroethyl)-ltyrosine. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 519–524. https://doi.org/10.1007/s00259-003-1118-0Galldiks N., Rapp M., Stoffels G., Dunkl V., Sabel M., Langen K.J. Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluorethyl)- L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. Mol. Imaging. 2013; 12: 273–276.Galldiks N., Rapp M., Stoffels G., Dunkl V., Sabel M., Langen K.J. Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluorethyl)- L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. Mol. Imaging. 2013; 12: 273–276.Bolcaen J., Lybaert K., Moerman L., Descamps B., Deblaere K., Boterberg T., Kalala J.P., Van den Broecke C., De Vos F., Vanhove C., Goethals I. Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats. Plos One. 2016; 11 (10): e0164208. https://doi.org/10.1371/journal.pone.0164208Bolcaen J., Lybaert K., Moerman L., Descamps B., Deblaere K., Boterberg T., Kalala J.P., Van den Broecke C., De Vos F., Vanhove C., Goethals I. Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats. Plos One. 2016; 11 (10): e0164208. https://doi.org/10.1371/journal.pone.0164208Langen K.J., Hamacher K., Weckesser M., Floeth F., Stoffels G., Bauer D., Coenen H.H., Pauleit D. O-(2-[18F]. fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 2006; 33: 287–294. https://doi.org/10.1016/j.nucmedbio.2006.01.002Langen K.J., Hamacher K., Weckesser M., Floeth F., Stoffels G., Bauer D., Coenen H.H., Pauleit D. O-(2-[18F]. fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 2006; 33: 287–294. https://doi.org/10.1016/j.nucmedbio.2006.01.002Muoio B., Giovanella L., Treglia G. Recent Developments of 18F-FET PET in Neuro-oncology. Curr. Med. Chem. 2018; 25 (26): 3061–3073. https://doi.org/10.2174/0929867325666171123202644Muoio B., Giovanella L., Treglia G. Recent Developments of 18F-FET PET in Neuro-oncology. Curr. Med. Chem. 2018; 25 (26): 3061–3073. https://doi.org/10.2174/0929867325666171123202644Albert N.L., Weller M., Suchorska B., Galldiks N., Soffietti R., Kim M.M., la Fougere C., Pope W., Law I., Arbizu J., Chamberlain M.C., Vogelbaum M., Ellingson B.M., Tonn J.C. Response Assessment in Neuro- Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18: 1199– 1208. https://doi.org/10.1093/neuonc/now058Albert N.L., Weller M., Suchorska B., Galldiks N., Soffietti R., Kim M.M., la Fougere C., Pope W., Law I., Arbizu J., Chamberlain M.C., Vogelbaum M., Ellingson B.M., Tonn J.C. Response Assessment in Neuro- Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18: 1199– 1208. https://doi.org/10.1093/neuonc/now058Chugani D.C., Chugani H.T., Muzik O., Shah J.R., Shah A.K., Canady A., Mangner T.J., Chakraborty P.K. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann. Neurol. 1998; 44: 858–866. https://doi.org/10.1212/WNL.0b013e3182a08f3fChugani D.C., Chugani H.T., Muzik O., Shah J.R., Shah A.K., Canady A., Mangner T.J., Chakraborty P.K. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann. Neurol. 1998; 44: 858–866. https://doi.org/10.1212/WNL.0b013e3182a08f3fNikolaou A., Thomas D., Kampanellou C., Alexandraki K., Andersson L.G., Sundin A., Kaltsas G. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. J. Endocrinol. Invest. 2010; 33 (11): 794–799. https://doi.org/10.3275/6936Nikolaou A., Thomas D., Kampanellou C., Alexandraki K., Andersson L.G., Sundin A., Kaltsas G. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. J. Endocrinol. Invest. 2010; 33 (11): 794–799. https://doi.org/10.3275/6936Schuster D.M., Nanni C., Fanti S., Oka S., Okudaira H., Inoue Y., Sörensen J., Owenius R., Choyke P., Turkbey B., Bogsrud T.V., Bach-Gansmo T., Halkar R.K., Nye J.A., Odewole O.A., Savir-Baruch B., Goodman M.M. Anti-1- amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J. Nucl. Med. 2014; 55 (12): 1986–1992. https://doi.org/10.2967/jnumed.114.143628Schuster D.M., Nanni C., Fanti S., Oka S., Okudaira H., Inoue Y., Sörensen J., Owenius R., Choyke P., Turkbey B., Bogsrud T.V., Bach-Gansmo T., Halkar R.K., Nye J.A., Odewole O.A., Savir-Baruch B., Goodman M.M. Anti-1- amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J. Nucl. Med. 2014; 55 (12): 1986–1992. https://doi.org/10.2967/jnumed.114.143628Odewole O.A., Tade F.I., Nieh P.T., Savir-Baruch B., Jani A.B., Master V.A., Rossi P.J., Halkar R.K., Osunkoya A.O., Akin-Akintayo O., Zhang C., Chen Z., Goodman M.M., Schuster D.M. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (10): 1773–1783. https://doi.org/10.1007/s00259-016-3383-8Odewole O.A., Tade F.I., Nieh P.T., Savir-Baruch B., Jani A.B., Master V.A., Rossi P.J., Halkar R.K., Osunkoya A.O., Akin-Akintayo O., Zhang C., Chen Z., Goodman M.M., Schuster D.M. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (10): 1773–1783. https://doi.org/10.1007/s00259-016-3383-8Akin-Akintayo O., Tade F., Mittal P., Moreno C., Nieh P.T., Rossi P., Patil D., Halkar R., Fei B., Master V., Jani A.B., Kitajima H., Osunkoya A.O., Ormenisan-Gherasim C., Goodman M.M., Schuster D.M. Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. Eur. J. Radiol. 2018; 102: 1–8. https://doi.org/10.1016/j.ejrad.2018.02.006Akin-Akintayo O., Tade F., Mittal P., Moreno C., Nieh P.T., Rossi P., Patil D., Halkar R., Fei B., Master V., Jani A.B., Kitajima H., Osunkoya A.O., Ormenisan-Gherasim C., Goodman M.M., Schuster D.M. Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. Eur. J. Radiol. 2018; 102: 1–8. https://doi.org/10.1016/j.ejrad.2018.02.006Akin-Akintayo O.O., Jani A.B., Odewole O., Tade F.I., Nieh P.T., Master V.A., Bellamy L.M., Halkar R.K., Zhang C., Chen Z., Goodman M.M., Schuster D.M. Change in salvage radiotherapy management based on guidance with FACBC (fluciclovine) PET-CT in postprostatectomy recurrent prostate cancer. Clin. Nucl. Med. 2017; 42 (1): e22–e28. https://doi.org/10.1097/RLU.0000000000001379Akin-Akintayo O.O., Jani A.B., Odewole O., Tade F.I., Nieh P.T., Master V.A., Bellamy L.M., Halkar R.K., Zhang C., Chen Z., Goodman M.M., Schuster D.M. Change in salvage radiotherapy management based on guidance with FACBC (fluciclovine) PET-CT in postprostatectomy recurrent prostate cancer. Clin. Nucl. Med. 2017; 42 (1): e22–e28. https://doi.org/10.1097/RLU.0000000000001379Parent E.E., Benayoun M., Ibeanu I., Olson J.J., Hadjipanayis C.G., Brat D.J., Goodman M.M. [18F] Fluciclovine PET discrimination between high- and lowgrade gliomas. EJNMMI research. 2018; 8 (1): 67. https://doi.org/10.1186/s13550-018-0415-3Parent E.E., Benayoun M., Ibeanu I., Olson J.J., Hadjipanayis C.G., Brat D.J., Goodman M.M. [18F] Fluciclovine PET discrimination between high- and lowgrade gliomas. EJNMMI research. 2018; 8 (1): 67. https://doi.org/10.1186/s13550-018-0415-3

The authors declare that there are no conflicts of interest present.